Matt Henriksen

Let's call it cost of goods sold burden to, for that capital component.

And then with that inventory build itself, how do you balance that pre-FDA approval?

Because you want to make sure you have enough product to get the launch going, but you need to focus on your cash burn as well.

And then how about the commercial team itself?

I mean, because there's, you know, dividing fields between a gradual build of the commercial team and a let's just build that commercial team now and get it done with so we don't have to keep worrying about further training, new training, all that stuff.

Yeah, that's interesting.

And what caught my attention, too, and what you just said was two-thirds of the cases are done east of the Mississippi.

Yeah.

But I know that, you know, the population is pretty close, 50-50, between east of the Mississippi, west of the Mississippi.

Is there a reason why, like, California and Arizona?

I mean, I feel like Arizona would just be like Florida with the retirees.

Like, is there a reason why the West Coast just has not picked up that techno?

Especially with Shockwave being out in California.

Okay.

That makes sense.

Yeah.

I guess we're not eating as much avocado toast here as we are out there, but.

Oh, all right.

So you got the commercial strategy.

And the other thing too, is it's interesting is we really haven't dove into how IVL can be used in both the coronary setting and the peripheral setting.